Skip to main content
. 2017 Oct 29;8(59):99245–99260. doi: 10.18632/oncotarget.22104

Figure 5. Combined treatment with 64B and 2-DG markedly retards tumor growth.

Figure 5

Mice received daily administration of 64B (60 mg/kg, i.p.) and/or 2-DG (1 g/kg, p.o.) for indicated duration (n = 5 mice/group). A, Treatment scheme (upper) and tumor growth curves (lower) in mice bearing orthotopic MDA-MB-231 breast tumors. The mice were treated for 14 days and sacrificed on day 28. B, Image and weight of MDA-MB-231 tumors harvested at termination. C, Average body weight of mice bearing MDA-MB-231 tumors during the entire course of the study. D, H&E staining and Ki-67 immunostaining of the MDA-MB-231 tumor sections. Images were acquired at 40× magnification. Quantification of Ki-67-positive cells was determined microscopically (mean cell number per field ± SD, 12 fields per tumor). E, Treatment scheme (upper) and tumor growth curves (lower) in mice bearing subcutaneous LLC tumors. The mice were treated for 10 days and sacrificed on day 12. F, Image and weight of LLC tumors harvested at termination. G, Average body weight of mice bearing LLC tumors during the entire course of the study. H, H&E staining and Ki-67 immunostaining of LLC tumor sections. Images were acquired at 40× magnification. Quantification of Ki-67-positive cells was determined microscopically (mean cell number per field ± SD, 12 fields per tumor). I, Kaplan-Meier survival curves in mice bearing subcutaneous LLC tumors. Mice were euthanized when the tumor size reached IACUC termination criteria.The results are reported as the mean ± SD (n = 5). *, p < 0.05. **, p < 0.01.